A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors

被引:25
|
作者
Chen, Kevin X. [1 ]
Lesburg, Charles A. [1 ]
Vibulbhan, Bancha [1 ]
Yang, Weiying [1 ]
Chan, Tin-Yau [1 ]
Venkatraman, Srikanth [1 ]
Velazquez, Francisco [1 ]
Zeng, Qingbei [1 ]
Bennett, Frank [1 ]
Anilkumar, Gopinadhan N. [1 ]
Duca, Jose [1 ]
Jiang, Yueheng [1 ]
Pinto, Patrick [1 ]
Wang, Li [1 ]
Huang, Yuhua [1 ]
Selyutin, Oleg [1 ]
Gavalas, Stephen [1 ]
Pu, Haiyan [1 ]
Agrawal, Sony [1 ]
Feld, Boris [1 ]
Huang, Hsueh-Cheng [1 ]
Li, Cheng [1 ]
Cheng, Kuo-Chi [1 ]
Shih, Neng-Yang [1 ]
Kozlowski, Joseph A. [1 ]
Rosenblum, Stuart B. [1 ]
Njoroge, F. George [1 ]
机构
[1] Merck Res Labs, Kenilworth, NJ 07033 USA
关键词
DEPENDENT RNA-POLYMERASE; ANTIVIRAL ACTIVITY; NONNUCLEOSIDE INHIBITORS; PROTEASE INHIBITOR; CRYSTAL-STRUCTURE; IN-VITRO; DISCOVERY; NUCLEOTIDE; DESIGN; IDENTIFICATION;
D O I
10.1021/jm201322r
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Starting from indole-based C-3 pyridone HCV NS5B polymerase inhibitor 2, structure-activity relationship (SAR) investigations of the indole N-1 benzyl moiety were performed. This study led to the discovery of irreversible inhibitors with p-fluoro-sulfone- or p-fluoro-nitro-substituted N-1 benzyl groups which achieved breakthrough replicon assay potency (EC50 = 1 nM). The formation of a covalent bond with adjacent cysteine-366 thiol was was proved by mass spectroscopy and X-ray crystal structure studies. The C-5 ethyl C-2 carboxylic acid derivative 47 had an excellent oral area-under-the-curve (AUC) of 18 mu M.h (10 mg/kg). Its oral exposure in monkeys and dogs was also very good. The NMR ALARM assay, mass spectroscopy experiments, in vitro counter screening, and toxicology assays demonstrated that the covalent bond formation between compound 47 and the protein was highly selective and specific. The overall excellent profile of 47 made it an interesting candidate for further investigation.
引用
收藏
页码:2089 / 2101
页数:13
相关论文
共 50 条
  • [1] Etodolac Thiosemicarbazides: A novel class of hepatitis C virus NS5B polymerase inhibitors
    Cikla, Pelin
    Arora, Payal
    Basu, Amartya
    Talele, Tanaji T.
    Kaushik-Basu, Neerja
    Kucukguzel, S. Guniz
    [J]. MARMARA PHARMACEUTICAL JOURNAL, 2013, 17 (02) : 138 - 146
  • [2] 4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors
    Kaushik-Basu, Neerja
    Bopda-Waffo, Alain
    Talele, Tanaji T.
    Basu, Amartya
    Chen, Ye
    Kucukguzel, S. Guniz
    [J]. FRONTIERS IN BIOSCIENCE, 2008, 13 : 3857 - 3868
  • [3] Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase
    LaPorte, MG
    Lessen, TA
    Leister, L
    Cebzanov, D
    Amparo, E
    Faust, C
    Ortlip, D
    Bailey, TR
    Nitz, TJ
    Chunduru, SK
    Young, DC
    Burns, CJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) : 100 - 103
  • [4] Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase
    Habermann, Joerg
    Capito, Elena
    Ferreira, Maria del Rosario Rico
    Koch, Uwe
    Narjes, Frank
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 633 - 638
  • [5] Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding
    Gopalsamy, Ariamala
    Chopra, Rajiv
    Lim, Kitae
    Ciszewski, Gregory
    Shi, Mengxiao
    Curran, Kevin J.
    Sukits, Steven F.
    Svenson, Kristine
    Bard, Joel
    Ellingboe, John W.
    Agarwal, Atul
    Krishnamurthy, Girija
    Howe, Anita Y. M.
    Orlowski, Mark
    Feld, Boris
    O'Connell, John
    Mansour, Tarek S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3052 - 3055
  • [6] A review on an update of NS5B polymerase hepatitis C virus inhibitors
    Varshney, J.
    Sharma, P. K.
    Sharma, A.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (05) : 667 - 671
  • [7] Selection and characterization of hepatitis C virus replicons resistant to potent NS5B polymerase inhibitors.
    Lu, LJ
    Mo, HM
    Pilot-Matias, T
    Dekhtyar, T
    Ng, T
    Pithawalla, R
    Masse, S
    Pratt, J
    Donner, P
    Maring, C
    Molla, A
    [J]. HEPATOLOGY, 2004, 40 (04) : 694A - 694A
  • [8] New NS5B polymerase inhibitors for hepatitis C
    Legrand-Abravanel, Florence
    Nicot, Florence
    Izopet, Jacques
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (08) : 963 - 975
  • [9] Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review
    Xie, Yuanchao
    Ogah, Comfort Alicha
    Jiang, Xiangrui
    Li, Jianfeng
    Shen, Jingshan
    [J]. CURRENT DRUG TARGETS, 2016, 17 (13) : 1560 - 1576
  • [10] Advanced Hepatitis C virus NS5B polymerase primer grip inhibitors
    Parcella, Kyle
    Eastman, Kyle
    Yeung, Kap-Sun
    Grant-Young, Katharine
    Zhu, Juliang
    Wang, Tao
    Zhang, Zhongxing
    Yin, Zhiwei
    Parker, Dawn
    Mosure, Kathy
    Beno, Brett
    Fang, Hua
    Wang, Ying-Kai
    Lemm, Julie
    Zhuo, Xiaoliang
    Hanumegowda, Umesh
    Johnson, Benjamin
    Haskell, Roy
    Krause, Rudolph
    Liu, Mengping
    Poronsky, Chris
    Rigat, Karen
    Sheriff, Steven
    Donoso, Maria
    Tuttle, Maria
    Huang, Xiaohua
    Meanwell, Nicholas
    Soars, Matt
    Roberts, Susan
    Kadow, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250